Researchorforgliprondanuglipronglp-1 receptor agonistmedicinal chemistry

Review maps design lessons from oral small-molecule GLP-1 agonists

Authors analyze danuglipron, lotiglipron, DA-302168S and orforglipron, the first approved oral small-molecule GLP-1 receptor agonist.

By Priya Raman · Science Reporter

Sep 23 20:00 ETSource: Journal of medicinal chemistry

The wire

01The Journal of Medicinal Chemistry review examines first-generation oral nonpeptidic GLP-1 receptor agonists as case studies and outlines peptidomimetic, multi-target and allosteric cooperativity strategies for next-generation compounds.
02It frames how the peptide-only barrier in incretin therapy was broken, relevant to anyone tracking where oral incretins and peptidomimetics go next.
03This is a review and design framework, not new clinical or preclinical data.

From the source

Oral Small-Molecule GLP-1 Receptor Agonists: Lessons from Clinical Candidates and a Blueprint for Next-Generation Design
Journal of medicinal chemistry · 2026 Sep 24 · Hu J, Zhang Y, Wang M et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42916694/